Cargando…

Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus

As an effective antiviral agent, the clinical application of oseltamivir (OTV) is limited by the appearance of drug-resistant viruses. Due to their low toxicity and excellent activity, the antiviral capabilities of selenium nanoparticles (SeNPs) has attracted increasing attention in recent years. To...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yinghua, Lin, Zhengfang, Guo, Min, Xia, Yu, Zhao, Mingqi, Wang, Changbing, Xu, Tiantian, Chen, Tianfeng, Zhu, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557909/ https://www.ncbi.nlm.nih.gov/pubmed/28848350 http://dx.doi.org/10.2147/IJN.S140939

Ejemplares similares

Inhibition of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with amantadine through ROS-mediated AKT signaling pathways
por: Li, Yinghua, et al.
Publicado: (2018)

The Inhibition of H1N1 Influenza Virus-Induced Apoptosis by Surface Decoration of Selenium Nanoparticles with β-Thujaplicin through Reactive Oxygen Species-Mediated AKT and p53 Signaling Pathways
por: Wang, Changbing, et al.
Publicado: (2020)

siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy
por: Xia, Yu, et al.
Publicado: (2018)

Restriction of H1N1 influenza virus infection by selenium nanoparticles loaded with ribavirin via resisting caspase-3 apoptotic pathway
por: Lin, Zhengfang, et al.
Publicado: (2018)

Multifunctional selenium nanoparticles as carriers of HSP70 siRNA to induce apoptosis of HepG2 cells
por: Li, Yinghua, et al.
Publicado: (2016)

Multifunctional selenium nanoparticles with Galangin-induced HepG2 cell apoptosis through p38 and AKT signalling pathway
por: Li, Yinghua, et al.
Publicado: (2018)

Selenium nanoparticles inhibited H1N1 influenza virus-induced apoptosis by ROS-mediated signaling pathways
por: Liu, Xia, et al.
Publicado: (2022)

Polyethylenimine-functionalized silver nanoparticle-based co-delivery of paclitaxel to induce HepG2 cell apoptosis
por: Li, Yinghua, et al.
Publicado: (2016)

Inhibition of H3N2 Influenza Virus Induced Apoptosis by Selenium Nanoparticles with Chitosan through ROS-Mediated Signaling Pathways
por: Xu, Tiantian, et al.
Publicado: (2023)

Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy
por: Xia, Yu, et al.
Publicado: (2017)

Folate-targeted selenium nanoparticles deliver therapeutic siRNA to improve hepatocellular carcinoma therapy
por: Xia, Yu, et al.
Publicado: (2018)

Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy
por: Xia, Yu, et al.
Publicado: (2018)

Targeted delivery of HES5-siRNA with novel polypeptide-modified nanoparticles for hepatocellular carcinoma therapy
por: Xia, Yu, et al.
Publicado: (2018)

Silver Nanoparticles Induce HePG-2 Cells Apoptosis Through ROS-Mediated Signaling Pathways
por: Zhu, Bing, et al.
Publicado: (2016)

Inhibition of Enterovirus 71 by Selenium Nanoparticles Loaded with siRNA through Bax Signaling Pathways
por: Lin, Zhengfang, et al.
Publicado: (2020)

Selenium-ruthenium complex blocks H1N1 influenza virus-induced cell damage by activating GPx1/TrxR1
por: Li, Yinghua, et al.
Publicado: (2023)

Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma
por: Xia, Yu, et al.
Publicado: (2019)

The inhibition of H1N1 influenza induced apoptosis by sodium selenite through ROS-mediated signaling pathways
por: Gong, Guifang, et al.
Publicado: (2020)

Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles
por: Xia, Yu, et al.
Publicado: (2018)

Selenium Nanoparticles Control H1N1 Virus by Inhibiting Inflammatory Response and Cell Apoptosis
por: Su, Jingyao, et al.
Publicado: (2023)

Oseltamivir- and Amantadine-Resistant Influenza Virus A (H1N1)
por: Cheng, Peter K.C., et al.
Publicado: (2010)

Oseltamivir- and Amantadine-Resistant Influenza Viruses A (H1N1)
por: Cheng, Peter K.C., et al.
Publicado: (2009)

Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007–08
por: Hauge, Siri H, et al.
Publicado: (2009)

Reduced Sensitivity of Influenza A (H5N1) to Oseltamivir
por: McKimm-Breschkin, Jennifer L., et al.
Publicado: (2007)

Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir
por: Reddy, David
Publicado: (2010)

Widespread Oseltamivir Resistance in Influenza A Viruses (H1N1), South Africa
por: Besselaar, Terry G., et al.
Publicado: (2008)

Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007–08
por: Hauge, Siri H., et al.
Publicado: (2009)

Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses
por: Kiso, Maki, et al.
Publicado: (2010)

Oseltamivir‐resistant influenza A 2009 H1N1 virus in immunocompromised patients
por: Couturier, Brianne A., et al.
Publicado: (2010)

Discovery of Novel Boron-Containing N-Substituted Oseltamivir Derivatives as Anti-Influenza A Virus Agents for Overcoming N1-H274Y Oseltamivir-Resistant
por: Jia, Ruifang, et al.
Publicado: (2022)

Oseltamivir compounding in the hospital pharmacy during the (H1N1) influenza pandemic
por: de Mário Marin, Márcia Lúcia, et al.
Publicado: (2010)

A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir
por: Matsuzaki, Yoko, et al.
Publicado: (2010)

Oseltamivir-Resistant Influenza Viruses A (H1N1) during 2007–2009 Influenza Seasons, Japan
por: Ujike, Makoto, et al.
Publicado: (2010)

Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season
por: Meijer, Adam, et al.
Publicado: (2009)

In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1
por: Tambunan, Usman Sumo Friend, et al.
Publicado: (2015)

Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus
por: Xu, Zhichao, et al.
Publicado: (2022)

Comparisons of oseltamivir‐resistant (H275Y) and concurrent oseltamivir‐susceptible seasonal influenza A(H1N1) virus infections in hospitalized adults, 2008–2009
por: Chan, Martin C. W., et al.
Publicado: (2012)

Functionalized selenium nanoparticles for targeted siRNA delivery silence Derlin1 and promote antitumor efficacy against cervical cancer
por: Xia, Yu, et al.
Publicado: (2019)

Genomic Diversity of Oseltamivir-Resistant Influenza Virus A (H1N1), Luxembourg, 2007–08
por: Gerloff, Nancy A., et al.
Publicado: (2009)

Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008
por: Dijkstra, Frederika, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8hs5qmlodnb51ls5deh9hulssv